MB
EWTX icon

MPM BioImpact’s Edgewise Therapeutics EWTX Stock Holding History

MPM BioImpact’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$65.9M Sell
1,620,780
-39,916
-2% -$1.38M 4.02% 6
2026
Q1 		$52.3M Buy
1,660,696
+5,440
+0.3% +$157K 4.04% 6
2025
Q4 		$41.1M Sell
1,655,256
-65,485
-4% -$1.31M 4.7% 5
2025
Q3 		$27.9M Hold
1,720,741
– – 4.57% 5
2025
Q2 		$22.6M Buy
1,720,741
+615,297
+56% +$8.87M 3.91% 6
2025
Q1 		$24.3M Buy
1,105,444
+26,128
+2% +$685K 4.18% 4
2024
Q4 		$28.8M Buy
1,079,316
+162,150
+18% +$5.16M 4.09% 3
2024
Q3 		$24.5M Buy
917,166
+176,505
+24% +$3.51M 3.67% 6
2024
Q2 		$13.3M Buy
740,661
+299,402
+68% +$5.22M 2.07% 15
2024
Q1 		$8.05M Buy
+441,259
New +$7.01M 1.29% 32
2023
Q3 		– Sell
-712,798
Closed -$5.52M – 33
2023
Q2 		$5.52M Buy
+712,798
New +$6.01M 1.11% 27
2022
Q4 		– Sell
-304,027
Closed -$2.99M – 39
2022
Q3 		$2.99M Buy
+304,027
New +$3.07M 0.71% 26

Other funds holding EWTX

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

MPM BioImpact's EWTX Position: Q2 2026 in Review

MPM BioImpact reduced its Edgewise Therapeutics (EWTX) stake by 2.4% in Q2 2026, selling an estimated $1.38M and leaving 1,620,780 shares worth $65.9M. The position accounts for 4.02% of the portfolio, ranked #6.

MPM BioImpact first reported a position in EWTX in Q3 2022 and has held it in 12 quarters since. 226 funds tracked by Wall St. Rank hold EWTX as of Q2 2026.

  • MPM BioImpact held 1,620,780 shares of Edgewise Therapeutics worth $65.9M as of Q2 2026.
  • MPM BioImpact sold 39,916 Edgewise Therapeutics shares in Q2 2026, an estimated $1.38M.
  • Edgewise Therapeutics made up 4.02% of MPM BioImpact's portfolio in Q2 2026, its #6 holding.
  • MPM BioImpact first reported a position in Edgewise Therapeutics in Q3 2022 and has held it in 12 quarters since.
  • 226 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q2 2026.

Based on MPM BioImpact's 13F filing for Q2 2026, filed 14 Aug 2026.